Rhythm Pharmaceuticals, Inc.

NasdaqGM RYTM

Rhythm Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -46.69 M

Rhythm Pharmaceuticals, Inc. Net Cash Used For Investing Activities is USD -46.69 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 32.41% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Rhythm Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -69.08 M, a -190.83% change year over year.
Rhythm Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 76.05 M, a 1,111.33% change year over year.
Rhythm Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -7.52 M, a 82.30% change year over year.
Rhythm Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -42.48 M, a -134.42% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: RYTM

Rhythm Pharmaceuticals, Inc.

CEO	Dr. David P. Meeker M.D.
IPO Date	Oct. 9, 2017
Location	United States
Headquarters	222 Berkeley Street
Employees	226
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Key trends

Past 5 years